Article

You have full text access to this OnlineOpen article

Structure of dystrophia myotonica protein kinase

  1. Jonathan M. Elkins1,*,
  2. Ann Amos1,
  3. Frank H. Niesen1,
  4. Ashley C.W. Pike1,
  5. Oleg Fedorov1,
  6. Stefan Knapp1,2,*

Article first published online: 10 FEB 2009

DOI: 10.1002/pro.82

Issue

Protein Science

Protein Science

Volume 18, Issue 4, pages 782–791, April 2009

Additional Information

How to Cite

Elkins, J. M., Amos, A., Niesen, F. H., Pike, A. C.W., Fedorov, O. and Knapp, S. (2009), Structure of dystrophia myotonica protein kinase. Protein Science, 18: 782–791. doi: 10.1002/pro.82

Author Information

  1. 1

    Structural Genomics Consortium, Nuffield Department of Medicine, Oxford University, Old Road Campus Research Building, Oxford, OX3 7DQ, United Kingdom

  2. 2

    Department of Clinical Pharmacology, Oxford University, Old Road Campus Research Building, Oxford, OX3 7DQ, United Kingdom

*Structural Genomics Consortium, Oxford University, Old Road Campus Research Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7DQ, UK

Publication History

  1. Issue published online: 25 MAR 2009
  2. Article first published online: 10 FEB 2009
  3. Accepted manuscript online: 10 FEB 2009 12:00AM EST
  4. Manuscript Accepted: 29 DEC 2008
  5. Manuscript Revised: 19 DEC 2008
  6. Manuscript Received: 23 SEP 2008

Funded by

  • Canadian Institutes for Health Research
  • Canadian Foundation for Innovation
  • Genome Canada (Ontario Genomics Institute)
  • GlaxoSmithKline
  • Karolinska Institutet
  • Knut and Alice Wallenberg Foundation
  • Ontario Innovation Trust
  • Ontario Ministry for Research and Innovation
  • Merck & Co., Inc.
  • Novartis Research Foundation
  • Swedish Agency for Innovation Systems
  • Swedish Foundation for Strategic Research
  • Wellcome Trust

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (475K)

References

  • 1
    Ranum LPW, Day JW ( 2004) Myotonic dystrophy: RNA Pathogenesis Comes into Focus. Am J Hum Genet 74: 793–804.
  • 2
    Day JW, Ranum LPW ( 2005) RNA pathogenesis of the myotonic dystrophies. Neuromuscular Disord 15: 5–16.
  • 3
    Wansink DG, Wieringa B ( 2003) Transgenic mouse models for myotonic dystrophy type 1 (DM1). Cytogenet Genome Res 100: 230–242.
  • 4
    Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LPW ( 2001) Myotonic Dystrophy Type 2 Caused by a CCTG Expansion in Intron 1 of ZNF9. Science 293: 864–867.
  • 5
    Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, Krym M, Thornton CA ( 2000) Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289: 1769–1773.
  • 6
    Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS ( 2003) A Muscleblind Knockout Model for Myotonic Dystrophy. Science 302: 1978–1980.
  • 7
    Miller JW, Urbinati CR, Teng-umnuay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS ( 2000) Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy. EMBO J 19: 4439–4448.
  • 8
    Fardaei M, Rogers MT, Thorpe HM, Larkin K, Hamshere MG, Harper PS, Brook JD ( 2002) Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet 11: 805–814.
  • 9
    Orengo JP, Chambon P, Metzger D, Mosier DR, Snipes GJ, Cooper TA ( 2008) Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. PNAS 105: 2646–2651.
  • 10
    Guiraud-Dogan C, Huguet A, Gomes-Pereira M, Brisson E, Bassez G, Junien C, Gourdon G ( 2007) DM1 CTG expansions affect insulin receptor isoforms expression in various tissues of transgenic mice. Biochim Biophys Acta 1772: 1183–1191.
  • 11
    Jansen G, Groenen PJTA, Bächner D, Jap PHK, Coerwinkel M, Oerlemans F, van den Broek W, Gohlsch B, Pette D, Plomp JJ, Molenaar PC, Nederhoff MGJ, van Echteld CJA, Dekker M, Berns A, Hameister H, Wieringa B ( 1996) Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nat Genet 13: 316–324.
  • 12
    Reddy S, Smith DBJ, Rich MM, Leferovich JM, Reilly P, Davis BM, Tran K, Rayburn H, Bronson R, Cros D, Balice-Gordon RJ, Housman D ( 1996) Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy. Nat Genet 13: 325–335.
  • 13
    Berul CI, Maguire CT, Aronovitz MJ, Greenwood J, Miller C, Gehrmann J, Housman D, Mendelsohn ME, Reddy S ( 1999) DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model. J Clin Invest 103: R1–R7.
  • 14
    Llagostera E, Catalucci D, Marti L, Liesa M, Camps M, Ciaraldi TP, Kondo R, Reddy S, Dillmann WH, Palacín M, Zorzano A, Ruiz-Lozano P, Gomis R, Kaliman P ( 2007) Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLo S ONE 2: e1134.
  • 15
    Mounsey JP, John JE, III, Helmke SM, Bush EW, Gilbert J, Roses AD, Perryman MB, Jones LR, Moorman JR ( 2000) Phospholemman is a substrate for myotonic dystrophy protein kinase. J Biol Chem 275: 23362–23367.
  • 16
    Murányi A, Zhang R, Liu F, Hirano K, Ito M, Epstein HF, Hartshorne DJ ( 2001) Myotonic dystrophy protein kinase phosphorylates the myosin phosphatase targetting subunit and inhibits myosin phosphatase activity. FEBS Lett 493: 80–84.
  • 17
    Kaliman P, Catalucci D, Lam JT, Kondo R, Gutiérrez JCP, Reddy S, Palacín M, Zorzano A, Chien KR, Ruiz-Lozano P ( 2005) Myotonic dystrophy protein kinase phosphorylates phospholamban and regulates calcium uptake in cardiomyocyte sarcoplasmic reticulum. J Biol Chem 280: 8016–8021.
  • 18
    Groenen, P.J.T.A., Wansink DG, Coerwinkel MM, van den Broek W, Jansen G, Wieringa B ( 2000) Constitutive and regulated modes of splicing produce six major myotonic dystrophy protein kinase (DMPK) isoforms with distinct properties. Hum Mol Genet 9: 605–616.
  • 19
    Garcia P, Ucurum Z, Bucher R, Svergun DI, Huber T, Lustig A, Konarev PV, Marino M, Mayans O ( 2006) Molecular insights into the self-assembly mechanism of dystrophia myotonica kinase. FASEB J 20: 1142–1151.
  • 20
    Tan I, Seow KT, Lim L, Leung T ( 2001) Intermolecular and intramolecular interactions regulate catalytic activity of myotonic dystrophy kinase-related cdc42-binding kinase α. Mol Cell Biol 21: 2767–2778.
  • 21
    Doran JD, Liu X, Taslimi P, Saadat A, Fox T ( 2004) New insights into the structure-function relationships of Rho-associated kinase: a thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications. Biochem J 384: 255–262.
  • 22
    Jacobs M, Hayakawa K, Swenson L, Bellon S, Fleming M, Taslimi P, Doran J ( 2006) The structure of dimeric ROCK1 reveals the mechanism for ligand selectivity. J Biol Chem 281: 260–268.
  • 23
    Yamaguchi H, Kasa M, Amano M, Kaibuchi K, Hakoshima T ( 2006) Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. Structure 14: 589–600.
  • 24
    Wansink DG, van Herpen, REMA, Coerwinkel-Driessen MM, Groenen, PJTA, Hemmings BA, Wieringa B ( 2003) Alternative splicing controls myotonic dystrophy protein kinase structure, enzymatic activity, and subcellular localization. Mol Cell Biol 23: 5489–5501.
  • 25
    Kannan N, Haste N, Taylor SS, Neuwald AF ( 2007) The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. PNAS 104: 1272–1277.
  • 26
    Narayana N, Cox S, Xuong, N-H, Ten Eyck LF, Taylor SS ( 1997) A binary complex of the catalytix subunit of cAMP-dependent protein kinase and adenosine further defines conformational flexibility. Structure 5: 921–935.
  • 27
    Xu Z-B, Chaudhary D, Olland S, Wolfrom S, Czerwinski R, Malakian K, Lin L, Stahl ML, Joseph-McCarthy D, Benander C, Fitz L, Greco R, Somers WS, Mosyak L ( 2004) Catalytic domain crystal structure of protein kinase C-θ (PKCθ). J Biol Chem 279: 50401–50409.
  • 28
    Gold MG, Barford D, Komander D ( 2006) Lining the pockets of kinases and phosphatases. Curr Opin Struct Biol 16: 693–701.
  • 29
    Zhao B, Lehr R, Smallwood AM, Ho TF, Maley K, Randall T, Head MS, Koretke KK, Schnackenberg CG ( 2007) Crystal structure of the kinase domain of serum and glucocorticoid-regulated kinase 1 in complex with AMP-PNP. Prot Sci 16: 1–9.
  • 30
    Messerschmidt A, Macieira S, Velarde M, Bädeker M, Benda C, Jestel A, Brandstetter H, Neuefeind T, Blaesse M ( 2005) Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif. J Mol Biol 352: 918–931.
  • 31
    Shimizu M, Wang W, Walch ET, Dunne PW, Epstein HF ( 2000) Rac-1 and Raf-1 kinases, components of distinct signaling pathways, activate myotonic dystrophy protein kinase. FEBS Lett 475: 273–277.
  • 32
    Dvorsky R, Blumenstein L, Vetter IR, Ahmadian MR ( 2004) Structural insights into the interaction of ROCK1 with the switch regions of RhoA. J Biol Chem 279: 7098–7104.
  • 33
    Bush EW, Helmke SM, Birnbaum RA, Perryman MB ( 2000) Myotonic dystrophy protein kinase domains mediate localization, oligomerization, novel catalytic activity, and autoinhibition. Biochemistry 39: 8480–8490.
  • 34
    Komander D, Garg R, Wan PTC, Ridley AJ, Barford D ( 2008) Mechanism of multi-site phosphorylation from a ROCK1:RhoE complex structure. EMBO J 27: 3175–3185.
  • 35
    Komander D, Kular GS, Schüttelkopf AW, Deak M, Prakash KRC, Bain J, Elliott M, Garrido-Franco M, Kozikowski AP, Alessi DR, van Aalten DMF ( 2004) Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1. Structure 12: 215–226.
  • 36
    Fedorov O, Marsden B, Pogacic V, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S ( 2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. PNAS 104: 20523–20528.
  • 37
    Leslie AGW ( 1999) Integration of macromolecular diffraction data. Acta Crystallogr. D55: 1696–1702.
  • 38
    Collaborative Computational Project Number 4 ( 1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D50: 760–763.
  • 39
    Storoni LC, McCoy AJ, Read RJ ( 2004) Likelihood-enhanced fast rotation functions. Acta Crystallogr D60: 432–438.
  • 40
    Emsley P, Cowtan K ( 2004) COOT: model-building tools for molecular graphics. Acta Crystallogr D60: 2126–2132.
  • 41
    Murshudov GN, Vagin AA, Lebedev A, Wilson KS, Dodson EJ ( 1999) Efficient anisotropic refinement of macromolecular structures using FFT. Acta Crystallogr D55: 247–255.
  • 42
    Brown PH, Schuck P ( 2006) Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys J 90: 4651–4661.
View Full Article with Supporting Information (HTML) Get PDF (475K)